Search results for "Endocrine Gland"

showing 10 items of 142 documents

Biphasic 24-Hour Variations in Cyclic GMP Accumulation in the Rat Pineal Gland Are Due to Corresponding Changes in the Activity of Cytosolic and Part…

2006

Various parameters of the rat pineal gland display a 24-h rhythm. However, nothing is known about possible 24-h variations in cyclic GMP (cGMP) metabolism. In the present study, 24-h variations in pineal gland cGMP accumulation were investigated by determining the increase in cGMP level with and without inhibitors of phosphodiesterase at different time points over a light/dark cycle (12/12 h). Furthermore, the activity of guanylate cyclase (GC) was determined under substrate-saturated conditions regarding the cytosolic and particulate forms of the enzyme. It has been found that cGMP accumulation and GC activity display biphasic 24-h variations with two peaks--one approximately 7 h after lig…

Malemedicine.medical_specialtyTime FactorsBiologyArginineNitric OxidePineal GlandBiochemistryNitric oxideRats Sprague-DawleyCellular and Molecular NeurosciencePineal glandchemistry.chemical_compoundCytosolInternal medicinemedicineAnimalsCircadian rhythmCyclic GMPchemistry.chemical_classificationomega-N-MethylargininePhosphodiesteraseMetabolismCircadian RhythmRatsEnzyme ActivationCytosolEnzymeEndocrinologymedicine.anatomical_structurechemistryBiochemistryGuanylate CyclaseEndocrine glandJournal of Neurochemistry
researchProduct

Image-Guided Thermal Ablation as an Alternative to Surgery for Papillary Thyroid Microcarcinoma: Preliminary Results of an Italian Experience

2021

PurposeTo report the results of our preliminary experience in treating patients with papillary thyroid microcarcinoma (PTMC) with image-guided thermal ablation, in particular estimating the feasibility, safety and short-term efficacyMaterials and MethodsFrom 2018 patients with cytologically proven PTMC < 10 mm were discussed in a multidisciplinary team and evaluated for feasibility of image-guided thermal ablation. In case of technical feasibility, the three possible alternatives (i.e., image-guided thermal ablation, surgery, and active surveillance) were discussed with patients. Patients who agreed to be treated with image guided thermal ablation underwent radiofrequency (RFA) or la…

Malemedicine.medical_specialtyrecurrencecomplicationsRadiofrequency ablationEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSedationThermal ablationPapillary Thyroid MicrocarcinomaThyroid function testslcsh:Diseases of the endocrine glands. Clinical endocrinology030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciencesthermal ablation0302 clinical medicineEndocrinologylawmedicineHumansLocal anesthesiapapillary thyroid microcarcinomaThyroid NeoplasmsRetrospective StudiesOriginal Researchlcsh:RC648-665medicine.diagnostic_testbusiness.industryMicrowave ablationThyroidectomyMiddle AgedCarcinoma PapillarySurgeryTreatment OutcomeSurgery Computer-Assisted030220 oncology & carcinogenesisthyroidectomylaser ablationFemaleLaser Therapyradiofrequency ablationmedicine.symptombusinessFrontiers in Endocrinology
researchProduct

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

2018

Abstract Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment with SRLs high dose regimens, pegvisomant (PEG) as monotherapy, or combined therapy with the addition of PEG or cabergoline to SRLs. A new pharmacological approach includes pasireotide, a second-generation SRL approved for patients who do not adequately respond to surgery and/or for whom surgery is not an option. No reports on efficacy and safety of combined therapy with pasireotide and p…

OncologyAdultMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPegvisomant030209 endocrinology & metabolismCase ReportAntineoplastic Agentslcsh:Diseases of the endocrine glands. Clinical endocrinologyRadiosurgerySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentCabergolineInternal medicineAcromegalymedicineHumansErgolinesSalvage TherapyCotreatmentlcsh:RC648-665Medical treatmentSomatostatin receptorbusiness.industryHuman Growth HormoneGeneral Medicinemedicine.diseasePrognosisResistantPasireotideHormonesPasireotidechemistry030220 oncology & carcinogenesisPegvisomantAcromegalyDrug Therapy CombinationAcromegaly; Cotreatment; Pasireotide; Pegvisomant; ResistantbusinessSomatostatinmedicine.drugBMC Endocrine Disorders
researchProduct

The New TNM Staging System for Thyroid Cancer and the Risk of Disease Downstaging

2018

In October 2016 the American Joint Committee on Cancer (AJCC) published the 8th edition of the AJCC/TNM cancer staging system and it has been introduced in clinical practice since 1st January 2018. The effect of most of the changes in the new edition was the downstaging of a significant number of patients into lower stages, reflecting their low risk of thyroid cancer-related death. One of the most relevant modification refers to the role of the microscopic extra-thyroidal tumor invasion, which is no longer considered as criterion for the classification of T3 tumors. With the present study we want to assess the impact of the changes of the new staging system and therefore we analyzed or casi…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismDownstaging; Staging system; Thyroid cancer; TNM 2018; Tumor invasion; Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismAggressive diseaseDiseaseTNM staging systemlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinethyroid cancerstaging systemMedicineStaging systemThyroid cancerCancer stagingOriginal Researchlcsh:RC648-665TNM 2018business.industryThyroidCancerdownstagingtumor invasionmedicine.diseaseDiabetes and Metabolismmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessFrontiers in Endocrinology
researchProduct

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk

2019

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male brea…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismPALB2Diseasemale breast cancerHyperestrogenismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerInternal medicineGenotypeCYP17A1Internal MedicineGenetic predispositionMedicine030212 general & internal medicineskin and connective tissue diseasesEstrogen Receptor Statusmale breast cancer; CYP17A1; CYP1B1; polymorphisms; male breast cancer risklcsh:RC648-665business.industryResearchmedicine.diseasemale breast cancer risk030220 oncology & carcinogenesisMale breast cancerCYP1B1medicine.symptombusinesspolymorphismsEndocrine Connections
researchProduct

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

2013

Little is known about patients with malignant digestive neuroendocrine tumours (MD-NETs). Although their incidence is increasing, MD-NETs remain a rare cancer, representing 1% of digestive cancers. Most MD-NETs are well-differentiated. MD-NET poorly differentiated carcinomas account for 20% of cases on average. Anatomical localisation of MD-NETs varied according to geographic region. Stage at diagnosis and prognosis for patients with MD-NETs in the general population are considerably worse than often reported from small hospital case series. Prognosis varies with tumour differentiation, anatomic site and histological subtype. There are significant differences in survival from MD-NETs among …

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryEndocrinology Diabetes and MetabolismPoorly differentiatedIncidence (epidemiology)PopulationGeneral MedicineRare cancerSmall hospitalNeuroendocrine TumorsEndocrinologyEndocrinologyInternal medicineEpidemiologyEndocrine Gland NeoplasmsmedicineEndocrine systemAnimalsHumansbusinesseducationDigestive cancerGastrointestinal NeoplasmsEuropean journal of endocrinology
researchProduct

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.

2021

Opinionlcsh:RC648-665biologybusiness.industryEndocrinology Diabetes and MetabolismGraves’ orbitopathyReceptors Thyrotropinthyroid eye diseaselcsh:Diseases of the endocrine glands. Clinical endocrinologyThyrotropin receptorGraves OphthalmopathyEndocrinologyCancer researchbiology.proteinMedicineBiomarker (medicine)AnimalsHumansbiomarkerAntibodyfunctional thyrotropin receptor antibodiesbusinessBiomarkersstimulatory TSH receptor antibodiesAutoantibodiesFrontiers in endocrinology
researchProduct

Early development of human Merkel cells.

1992

Human fetal Merkel cells are now generally considered to be epidermal derivatives. Previous studies using antibodies against the simple epithelial cytokeratins (CKs), 8 and 18, have demonstrated the presence of these cells in the epidermis at as early as fetal week 10 to 12. Using antibodies against CK 20 whose expression within the skin is restricted to Merkel cells, we applied immunofluorescence and immunoperoxidase microscopy to analyze earlier embryonic and fetal human skin (wk 7 to 9). We were able to demonstrate the first Merkel cells at as early as fetal wk 8, i.e., at the same time as the epidermis starts to develop an intermediate, third layer, characterized by the expression of CK…

Pathologymedicine.medical_specialtyFluorescent Antibody TechniqueHuman skinGestational AgeDermatologyKeratin-20BiologyImmunofluorescenceBiochemistryImmunoenzyme TechniquesBasal (phylogenetics)FetusIntermediate Filament ProteinsEndocrine GlandsmedicineHumansMolecular BiologyFetusintegumentary systemImmunoperoxidasemedicine.diagnostic_testAntibodies MonoclonalEmbryonic stem cellmedicine.anatomical_structureEpidermal CellsEpidermisEpidermisMerkel cellHairExperimental dermatology
researchProduct

Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics

2017

Background: Anaplastic thyroid cancer (ATC) is a rare but extremely aggressive cancer of the thyroid, contributing up to 30-40% of thyroid cancer-specific mortality. We analyzed ATC characteristics and survival rates in Sicily to evaluate the possible influence of environmental factors. With this aim data regarding ATC incidences in urban/rural and industrial, iodine deficient and volcanic vs. control areas were compared in Sicily as well as ATC data from Sicily and USA. Methods: Using the Sicilian Register of Thyroid Cancer (SRTC) database incidence, age, gender, tumor size and histotype, extrathyroidal extension, stage and coexistence with pre-existing differentiated thyroid cancer (DTC) …

Pathologymedicine.medical_specialtyMultivariate analysisThyroid Cancer Registrythyroid cancer and volcanic environmentEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyPapillary thyroid cancer03 medical and health sciences0302 clinical medicineEndocrinologySurveillance Epidemiology and End Resultsthyroid cancerMedicineAnaplastic thyroid cancerThyroid cancerthyroid cancer epidemiologyOriginal ResearchUnivariate analysislcsh:RC648-665business.industryIncidence (epidemiology)Thyroidmedicine.diseaseDiabetes and Metabolismmedicine.anatomical_structure030220 oncology & carcinogenesisAnaplastic thyroid cancer; Thyroid cancer; Thyroid cancer and volcanic environment; Thyroid cancer epidemiology; Thyroid Cancer Registry; Endocrinology Diabetes and MetabolismbusinessDemographyanaplastic thyroid cancerFrontiers in Endocrinology
researchProduct

Medullary Thyroid Carcinoma With Exon 2 p.L56M RET Variant: Clinical Particular Features in Two Patients

2018

RET (REarranged during Transfection) proto-oncogene variants are essential for the development of familial and sporadic forms of medullary thyroid carcinoma (MTC). The most frequent variants are usually located in exons 10, 11, and 13 through 16 of the RET gene. We report two cases of apparently sporadic MTC associated with the variant in exon 2 of RET gene. Patient 1, a 62-year old man who had undergone adrenalectomy for a 5 cm pheochromocytoma, was screened for type 2 multiple endocrine neoplasia (MEN 2) which showed elevated basal and post-intravenous calcium gluconate calcitonin levels. A fine needle aspiration biopsy (FNAB) confirmed the suspicion of MTC. The patient underwent total th…

Pathologymedicine.medical_specialtyendocrine systemMedullary cavityendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismCase ReportL56M; Medullary thyroid carcinoma; MEN2; Pheochromocytoma; RET; Endocrinology Diabetes and Metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyThyroid carcinomaPheochromocytoma03 medical and health sciences0302 clinical medicineEndocrinologymedullary thyroid carcinomaBiopsymedicineMultiple endocrine neoplasialcsh:RC648-665medicine.diagnostic_testbusiness.industrySettore MED/13 - ENDOCRINOLOGIAHyperplasiamedicine.diseasepheochromocytomaDiabetes and MetabolismFine-needle aspirationMEN2Calcitonin030220 oncology & carcinogenesisbusinessRETL56MFrontiers in Endocrinology
researchProduct